A Phase I, Open-Label, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of a Single Oral Dose of RVX000222 in Subjects with Severe Renal Impairment.

Trial Profile

A Phase I, Open-Label, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of a Single Oral Dose of RVX000222 in Subjects with Severe Renal Impairment.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Apabetalone (Primary)
  • Indications Acute coronary syndromes; Alzheimer's disease; Low HDL cholesterol; Prediabetic-state
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Resverlogix Corporation
  • Most Recent Events

    • 30 Aug 2017 Results presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 29 Aug 2017 Data from this trial presented at the European Society of Cardioligists (ESC) Congress 2017, according to a Resverlogix Corporation media release.
    • 23 Jan 2017 Results published in a Resverlogix Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top